androgen deprivation therapy

Apalutimide for Prostate Cancer: What to Know
Apalutimide for Prostate Cancer: What to KnowFDA approves apalutamide for castration-resistant prostate cancer.
Slow breathing technique helps reduce hot flashesA slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.
Prostate Ca: PSA drop, active surveillance are key themesFusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
Greater long-term side effect risk with intermittent ADTIn men with metastatic prostate cancer, those assigned to intermittent androgen deprivation therapy have more ischemic and thrombotic events than those assigned to continuous androgen deprivation, according to Columbia University researchers.
Collaboration urged in managing ADT-related CV riskPhysicians at Vanderbilt University Medical Center, Nashville, have opened a dedicated cardio-oncology service, including urology, medical oncology, radiation oncology, and cardiology.
PCa castration study fuels surgery vs. GnRHA debateResults of a recently published study examining the safety of the two approaches support stronger consideration for orchiectomy, according to its authors.
Primary androgen therapy linked to reduced survival
Primary androgen therapy linked to reduced survivalUse of primary androgen deprivation therapy in men with localized prostate cancer is associated with decreased survival compared to men who receive no active treatment, according to new research findings.
Low bisphosphonate use seen in men on ADT
Low bisphosphonate use seen in men on ADTUse of bisphosphonates in men on androgen deprivation therapy (ADT) for prostate cancer remains low despite the fact that the practice is recommended in several guidelines, Canadian researchers say.
November 2014 New Products: Wearable coil facilitates positioning during prostate MRIOther products featured include a 16-slice CT scanner, new generic testosterone gel, prostate cancer risk calculator, and more.
ADT and CV risk: Two studies offer new insightsTwo recently published studies provide new insight on cardiovascular morbidity and mortality associated with androgen deprivation therapy in men with prostate cancer.